Is There a Role for Immunotherapy in Central Nervous System Cancers?

Journal Article (Journal Article;Review)

Glioblastoma has emerged as an immunotherapy-refractory tumor based on negative phase III studies of anti-programmed cell death-1 therapy among newly diagnosed as well as recurrent patients. In addition, although much work on vaccine and cellular approaches is ongoing, therapeutic benefit with these approaches has been underwhelming. Much scientific insight into the multitiered layers of immunosuppression exploited by glioblastoma tumors is emerging that sheds light on the explanation for the disappointing results to date and highlights possible therapeutic avenues that may offer a better likelihood of therapeutic benefit for immune-based therapies.

Full Text

Duke Authors

Cited Authors

  • Flores, C; Dunn, G; Fecci, P; Lim, M; Mitchell, D; Reardon, DA

Published Date

  • February 2022

Published In

Volume / Issue

  • 36 / 1

Start / End Page

  • 237 - 252

PubMed ID

  • 34801163

Electronic International Standard Serial Number (EISSN)

  • 1558-1977

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2021.09.002


  • eng

Conference Location

  • United States